Low-Dose Treatment with Erythropoiesis-Stimulating Agents and Cardiovascular Geometry in Chronic Kidney Disease: Is Darbepoetin-α More Effective than Expected?

Cardiorenal medicine

Luca Di Lullo ; Fulvio Floccari ; Antonio Granata ; Moreno Malaguti

关键词: Chronic kidney disease;    Darbepoetin-α;    Epoetin-α;    Hemodialysis;   

DOI  :  10.1159/000334942

学科分类：心脏病和心血管学

来源: S Karger AG

【 摘 要 】

Abstract Introduction: Chronic kidney disease (CKD) is a widespread invalidating condition, leading to erythropoietin deficiency and decreased cardiovascular performance. Darbepoetin- and epoetin- are extensively used to correct renal anemia. The aim of this study was to evaluate cardiological outcomes in two groups of CKD patients treated with erythropoiesis-stimulating agents (ESA: 20 g darbepoetin- weekly vs. 2,000 IU epoetin- thrice weekly) with an unconventional 1:300 conversion ratio. Meth.

【 授权许可】

CC BY